Presentation is loading. Please wait.

Presentation is loading. Please wait.

Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge by Chris A. R. Baker, Louise Swainson, Din L.

Published byHans Fischer Modified over 5 years ago

Similar presentations

Presentation on theme: "Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge by Chris A. R. Baker, Louise Swainson, Din L."— Presentation transcript:

1 Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge by Chris A. R. Baker, Louise Swainson, Din L. Lin, Samson Wong, Dennis J. Hartigan-O’Connor, Jeffrey D. Lifson, Alice F. Tarantal, and Joseph M. McCune Sci Transl Med Volume 7(300):300ra ra125 August 12, 2015 Copyright © 2015, American Association for the Advancement of Science

2 Fig. 1. Study design. Study design. (A) Timeline of immunizations and virus challenges. Fetal macaques were injected with SIVmac1A11 or PBS in the late first trimester (55 ± 5 days gestation; term 165 ± 10 days). Animals were then delivered by cesarean section at full term and immunized with either PBS or SIV antigens as neonates. At 16 weeks postnatal age, each animal was orally challenged with SIVmac239. Animals that did not demonstrate productive infection were then challenged intravenously between 37 and 57 weeks of age with SIVmac239 and followed for disease progression. IV, intravenous. (B) Summary of study groups. Chris A. R. Baker et al., Sci Transl Med 2015;7:300ra125 Copyright © 2015, American Association for the Advancement of Science

Download ppt "Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge by Chris A. R. Baker, Louise Swainson, Din L."

Similar presentations

Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies by Xiangguo Qiu, Jonathan Audet, Gary Wong, Stephane Pillet,

Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies by Xiangguo Qiu, Jonathan Audet, Gary Wong, Stephane Pillet,
Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates by Gary Wong, Jason S. Richardson, Stéphane.

Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates by Gary Wong, Jason S. Richardson, Stéphane.
Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.
Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice
G. Pialoux, C. Delaugerre, L. Cotte, F. Raffi, E. Cua, J.-M. Molina 

G. Pialoux, C. Delaugerre, L. Cotte, F. Raffi, E. Cua, J.-M. Molina 
Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.
Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.
Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.
Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Filipin staining of marginal gyrus of cerebral cortex in NPC cats
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.
Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.
Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Similar presentations

Ads by Google